HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.